Scotland backs two myeloma drugs turned down by NICE in EnglandA north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) Share XScotland backs two myeloma drugs turned down by NICE in Englandhttps://pharmaphorum.com/news/scotland-backs-two-myeloma-drugs-tuned-down-by-nice-in-england/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Amgen offers hope in KRAS-mutated cancer with sotorasib read-outLast year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug Share XAmgen offers hope in KRAS-mutated cancer with sotorasib read-outhttps://pharmaphorum.com/news/amgen-offers-hope-in-kras/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
Amgen and science education: the pharmaphorum podcastHarvard University launched LabXchange in January and the free science education platform acquired new resonance during the COVID-19 Share XAmgen and science education: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/amgen-labxchange-harvard-science-education/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Amgen to test psoriasis pill Otezla in COVID-19Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by Share XAmgen to test psoriasis pill Otezla in COVID-19https://pharmaphorum.com/news/amgen-to-test-psoriasis-pill-otezla-in-covid-19/
